Company intelligence / Profile preview
CRISPR Therapeutics
Zug, Switzerlandcrisprtx.com ↗
- Ownership
- Public · CRSP
- Employees
- ~393
- Development stage
- Commercial
01
Overview
CRISPR Therapeutics achieved historic regulatory approvals for CASGEVY™ (exagamglogene autotemcel [exa-cel], formerly CTX001) in the US, UK, Bahrain and EU for sickle cell disease and transfusion-dependent beta thalassemia. Clinical data show robust efficacy with high rates of transfusion independence or elimination of vaso-occlusive crises. The company has additional programs in immuno-oncology and regenerative medicine at various clinical stages[4][8][10].
- Therapeutic areas
- HematologyEndocrinologyOncology
- Modalities
- Gene editing (CRISPR/Cas9)ex vivo cell therapyallogeneic CAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
31 assets30 more assets in the full pipeline.
Request access →03
Partnerships
Vertex Pharmaceuticals (co-development/commercialization of exa-cel/CASGEVY™)Bayer AG/Bayer Life Science CenterViaCyte Inc. for diabetes program[4][8].
04
Financials
- Market cap
- $5B
- Total revenue
- $10.2M
- Enterprise value
- $3.5B
Beyond the preview
Go deeper on CRISPR Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRISPR Therapeutics.